12:00 AM
Aug 27, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cicletanine: Development discontinued

Gilead discontinued development of cicletanine to treat PAH after a double-blind, international Phase II trial showed that the product missed the primary endpoint of improving 6MWD from baseline to week 12 vs. placebo. Patients received placebo, once- or twice-daily 150 mg oral cicletanine or once-daily 300 mg oral cicletanine with or without...

Read the full 236 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >